October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
July 2025 in “Indian Dermatology Online Journal” Switching insulin brands caused skin lesions in a diabetic woman, resolved by changing to oral medication.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
1 citations
,
January 2025 in “ARC Journal of Dermatology”
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
January 2025 in “Cermin Dunia Kedokteran” Hypoglycemia in diabetes needs quick treatment to prevent serious health issues.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
13 citations
,
October 2017 in “Bioorganic & Medicinal Chemistry” Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
5 citations
,
August 2024 in “Cureus” GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
40 citations
,
December 2023 in “Acta Pharmacologica Sinica”
May 2026 in “Open Access CRIS of the University of Bern” GLP-1 receptor agonists can both help and harm hair, so careful monitoring is needed.
May 2023 in “Journal of Investigative Dermatology” Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
1 citations
,
May 1992 in “Pharmacological Research”
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
4 citations
,
February 2025 in “Pharmaceuticals” Voglibose may help treat skin hyperpigmentation safely.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for managing PCOS-related risks.
29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
June 2025 in “Mağallaẗ ʻulūm al-rāfidayn” Combining metformin with amoxicillin/clavulanate lowers blood sugar in diabetic female rats.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
July 2022 in “Journal of Investigative Dermatology” Blocking DPP4 can help activate hair growth and improve hair regeneration.